甘精胰島素聯(lián)合那格列奈強(qiáng)化治療初發(fā)2型糖尿病療效探究
發(fā)布時(shí)間:2018-06-24 來(lái)源: 美文摘抄 點(diǎn)擊:
[摘要] 目的 針對(duì)初發(fā)2型糖尿病患者實(shí)施甘精胰島素聯(lián)合那格列奈強(qiáng)化治療,進(jìn)一步評(píng)價(jià)聯(lián)合用藥的療效。方法 該次入選的初發(fā)2型糖尿病患者92例,納入時(shí)間跨度為2015年1月—2016年1月,按隨機(jī)抽樣法分成兩組,每組46例;對(duì)照組患者單用那格列奈進(jìn)行醫(yī)治,觀察組患者則實(shí)施甘精胰島素聯(lián)合那格列奈強(qiáng)化治療,對(duì)兩組臨床治療效果進(jìn)行比較評(píng)價(jià)。結(jié)果 在空腹血糖(FBG)、餐后2 h血糖(2 hPBG)以及糖化血紅蛋白(HbA1c)3項(xiàng)指標(biāo)水平,治療前兩組比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05);經(jīng)積極治療后,觀察組改善效果均顯著優(yōu)于對(duì)照組(P<0.05)。在胰島素分泌指數(shù)(HOMA-β)、胰島素抵抗指數(shù)(HOMA-IR)兩項(xiàng)指標(biāo)水平方面,治療前兩組比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05);經(jīng)積極治療后,觀察組改善效果均明顯優(yōu)于對(duì)照組(P<0.05)。結(jié)論 對(duì)于初發(fā)2型糖尿病患者,給予甘精胰島素聯(lián)合那格列奈強(qiáng)化治療具備顯著療效,可改善患者血糖水平,進(jìn)一步改善患者生活質(zhì)量;因此值得采納及使用。
[關(guān)鍵詞] 甘精胰島素;那格列奈;強(qiáng)化治療;初發(fā)2型糖尿。化熜
[中圖分類號(hào)] R587.1 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1672-4062(2017)11(b)-0003-02
[Abstract] Objective To further evaluate the curative effect of insulin glargine combined with nateglinide in intensive treatment of initial type 2 diabetes. Methods 92 cases of initial type 2 diabetes patients from January 2015 to January 2016 were selected and randomly divided into two groups with 46 cases in each, the control group were treated with single nateglinide, while the observation group were treated with insulin glargine combined with nateglinide, and the clinical treatment effect was compared and evaluated. Results There were no obvious differences in the FBG, 2 hPBG and HbA1c levels between the two groups before treatment(P>0.05), after the positive treatment, the improvement effect in the observation group was obviously better than that in the control group(P<0.05), and there wre no obvious differences in the HOMA-β and HOMA-IR levels between the two groups before treatment(P>0.05), after the positive treatment, the improvement effect in the observation group was obviously better than that in the control group(P<0.05). Conclusion The curative effect of insulin glargine combined with nateglinide in intensive treatment of initial type 2 diabetes is obvious, which can improve the blood glucose level and further improve the quality of life, therefore, it is worth recommendation and application.
[Key words] Insulin glargine; Nateglinide; Intensive treatment; Initial type 2 diabetes; Curative effect
2型糖尿病是內(nèi)分泌科常見(jiàn)的一種疾病,中老年人、有家族史者以及肥胖者是多發(fā)群體,該類患者主要的臨床癥狀為多飲、多尿、多食以及疲乏無(wú)力等等[1-2]。臨床建議,針對(duì)初發(fā)2型糖尿病患者,有必要在明確診斷的基礎(chǔ)上,采取及時(shí)有效的治療方案[3-4]。該次選取2015年1月—2016年1月收治的92例初發(fā)2型糖尿病患者作為研究的對(duì)象,主要是對(duì)甘精胰島素聯(lián)合那格列奈強(qiáng)化治療在其中的療效進(jìn)行分析及評(píng)價(jià),現(xiàn)報(bào)道如下。
1 資料與方法
1.1 一般資料
該次納入研究的92例初發(fā)2型糖尿病患者,均符合世界衛(wèi)生組織(WHO)中有關(guān)“初發(fā)2型糖尿病”的診斷標(biāo)準(zhǔn),排除嚴(yán)重肝、腎、心等重要臟器疾病者、妊娠婦女以及有糖尿病并發(fā)癥者。按隨機(jī)抽樣方法分為兩組,觀察組46例中,男性26例、女性20例;年齡分布在47~73歲,年齡均值為(56.8±1.3)歲;體質(zhì)指數(shù)(BMI)為(23.6±1.1)kg/m2。對(duì)照組46例中,男性26例、女性20例;年齡分布在46~74歲,年齡均值為(56.9±1.2)歲;體質(zhì)指數(shù)(BMI)為(23.7±1.2)kg/m2。在一般資料方面,兩組比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05),具備納入比較研究的意義。
熱點(diǎn)文章閱讀